The popular HIV treatment drug Truvada contains a medication called tenofovir disoproxil fumarate (TDF) which has recently been found to cause a number of adverse health effects. Truvada and other TDF-containing drugs are known to cause bone density loss.

Gilead Sciences, the distributor of Truvada, have knowingly delayed the release of a much safer HIV treatment drug containing tenofovir alafenamide (TAF) in order to maximize sales of Truvada. A lawsuit has been filed against Gilead Sciences for failing to warn consumers of the dangerous side effects of Truvada.